A phase I and randomised phase II study of docetaxel and RAD001 (everolimus) in advanced/recurrent or metastatic squamous cell carcinoma of the head and neck.
Phase of Trial: Phase I/II
Latest Information Update: 30 Jan 2014
At a glance
- Drugs Docetaxel (Primary) ; Everolimus (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DORA
- 31 Aug 2018 Biomarkers information updated
- 31 May 2012 Actual end date changed from Aug 2009 to 12 Apr 2011 as reported by UKCRN.
- 31 May 2012 Status changed from recruiting to completed as reported by UKCRN.